Why Your Weight Loss Has Stalled on Mounjaro (and What's Actually Happening)

The biggest myth: a stall means Mounjaro isn't working for you

The most common reason people contact us during a plateau is the belief that their body has somehow become resistant to tirzepatide, or that they are one of the rare non-responders. In most cases, neither is true. What is happening is more straightforward: as you lose weight, your resting metabolic rate decreases. A body that weighed 100 kg burns more calories at rest than one that now weighs 85 kg. Tirzepatide's appetite-suppressing effect has not weakened; your energy balance has simply shifted, and the deficit that produced rapid early loss has narrowed.

The SURMOUNT-1 trial (which followed adults on tirzepatide for 72 weeks and reported average weight reductions of around 20–21% at the highest dose) showed that loss was not linear throughout. Participants experienced variable rates of reduction at different points in the programme. A quiet month on the scale during an active treatment period is consistent with what the clinical data show. You can read more about how results unfold over time on our guide to weight loss on Mounjaro.

True non-response (defined by NICE as less than 5% weight loss after six months at the highest tolerated dose) is a clinical question for your prescriber, not a self-diagnosis to reach mid-treatment after a few slow weeks. If you are concerned that your weight loss has stalled on Mounjaro and you have been on the same dose for several months without movement, that is the time to discuss the picture with a clinician.

What actually drives a plateau during tirzepatide treatment

Several overlapping factors tend to converge when progress slows. The most common is physiological adaptation: a lighter body needs fewer calories, so the same eating habits that produced a deficit at the start of treatment may now produce near-balance. This is not unique to Mounjaro (it occurs on any weight-loss intervention) but it can feel surprising when appetite suppression is still present and you are eating less than you used to.

Dose is the second major variable. Mounjaro is titrated from 2.5 mg upward in four-weekly steps, and many people experience a renewed period of loss each time the dose increases. If weight loss has stalled and you are not yet at the highest dose your prescriber considers appropriate, moving up may be the most straightforward next step. This is a clinical decision: your prescriber will want to know how well you have tolerated the current dose before recommending a change. Our page on how long Mounjaro takes to work covers what a typical titration timeline looks like.

A third factor that often goes unexamined is protein intake. When appetite falls sharply, people sometimes eat less without eating differently, reducing total calories but losing an disproportionate amount of muscle mass alongside fat. Muscle tissue is metabolically active, so losing it accelerates the fall in resting energy expenditure, compounding the plateau. Our page on the Mounjaro weight loss stall explains why adequate protein and some resistance exercise are not optional extras on GLP-1 treatment, as they are the things most likely to preserve your metabolic rate through a stall.

Sleep, stress and the variables most people overlook

Sleep quality is underrated as a factor in weight-loss progress. Poor sleep raises cortisol and disrupts appetite-regulating hormones independently of what tirzepatide is doing. If a plateau has coincided with a period of disrupted nights (a new job, a sick child, anything that has moved your pattern) that connection is worth noting when you speak to your prescriber. It does not mean treatment is failing; it means the medicine is working within a system that has other pressures acting on it.

Stress-driven eating is another quiet disruptor. Tirzepatide reduces appetite, but it does not eliminate emotional or habitual eating triggers entirely. Some people find that earlier in treatment the appetite suppression was dramatic enough to override those triggers; as they adjust to the medicine, old habits can creep back in ways that are easy to miss. Keeping a brief food log for a week or two (not to restrict further, but to get an honest picture) is something our prescribers often suggest at this stage. You can reach them directly through our aftercare support line.

It is also worth checking whether any other medicines or supplements you have started recently might be affecting the picture. Some medications interact with how tirzepatide behaves. Your prescriber is the right person to review this; the NHS tirzepatide page lists the main drug interactions in plain language if you want to read ahead of that conversation.

When to treat the plateau as a clinical signal rather than a passing phase

Most stalls resolve within four to eight weeks if the factors above are addressed: adequate protein, consistent sleep, reassessing portion habits, and (where appropriate) a prescriber-directed dose increase. A plateau that runs beyond that with no other explanation is worth a clinical conversation sooner rather than later.

A few situations warrant contacting a prescriber promptly regardless of how long the stall has lasted: if you have also noticed that the appetite suppression itself feels weaker than it did, if you have recently taken a planned break from treatment (which can reset some of the medicine's early effect, see our page on breaks from Mounjaro), or if the scale is moving in the wrong direction consistently over several weeks. These are not causes for alarm, but they are useful data for a prescriber who can review your full picture.

For context on what private treatment involves and what to expect from ongoing clinical support, our Mounjaro overview sets out the full picture. If you are considering whether a prescription review or a fresh consultation is the right next step, our prescribers at the treatment page can assess your situation individually. Worth a conversation before drawing conclusions from a quiet month on the scale.